Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyAssessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsUnraveling the pathogenesis of HIV peripheral neuropathy: insights from a simian immunodeficiency virus macaque modelConformationally constrained nucleoside phosphonic acids--potent inhibitors of human mitochondrial and cytosolic 5'(3')-nucleotidasesIn vivo assessment of mitochondrial toxicity of metacavir in Rhesus monkeys after three months of intravenous administration.Liver disease, HIV and aging.Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.Portable lactate analyzer for measuring lactate in cerebrospinal fluid (CSF) and plasma - method-comparison evaluationsInhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme.Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialChanging patterns in the neuropathogenesis of HIV during the HAART era.Lactic acidosis in HIV infected patients: a systematic review of published cases.Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.Pharmacologic perspectives for once-daily antiretroviral therapy.Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Insights into the Molecular Mechanism of Polymerization and Nucleoside Reverse Transcriptase Inhibitor Incorporation by Human PrimPol.Health-related quality of life and physical functioning in people living with HIV/AIDS: a case-control design.Idiosyncratic drug-induced liver injury: an overview.Effects of zidovudine and stavudine on mitochondrial DNA of differentiating 3T3-F442a cells are not associated with imbalanced deoxynucleotide pools.Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infectionThe DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial ToxicityL-acetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathiesPharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyInterference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells.Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme.A review of the toxicity of HIV medications.Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.HIV treatment and associated mitochondrial pathology: review of 25 years of in vitro, animal, and human studies.Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy.Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in AccraMolecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs).
P2860
Q24243499-6766BF86-985E-483E-80F7-09B075C6A754Q24536268-274C14DF-1B27-41BA-99F1-FA37D7B32745Q26825231-B4984DE8-F327-4021-A6B7-173C119FFED1Q27694878-84416DB7-E2B5-47A4-AF43-52989861F432Q30885827-036A0101-64D5-4CEE-A987-44AD91EA258EQ33810577-770B8581-AD2B-4F48-9E32-79EDB7AE38C1Q34282667-F36FBD64-9E9E-401E-A6ED-79747F9D0A6EQ34289964-AF9B3191-1E1C-4FC4-B702-64D492942F2BQ34371989-C011E547-5583-4242-BC36-4A2AD79CA367Q34631672-D044C19C-B743-4EFA-8F97-C7B7BEC76EB4Q34657368-96CBA9FE-793D-4DF5-83E2-B2E4E79B0BB3Q34691336-65A4C3E8-48DD-438F-9B20-17B57E0287C1Q34932672-A372CE0E-01A1-4BE8-8333-527E08F2BC7EQ34952127-F5788E66-FACD-4FF7-A5A1-C6ECCE7FE3C7Q35126422-AF503450-045A-4391-A893-50272857802AQ35193807-9CEDCC56-DD1B-4A27-B3C6-6C42947EEFD5Q35327135-2978D0E6-02EA-40BC-8D48-BC070D3AEA85Q35676408-C4F174BC-1A11-4C38-A505-C50A465AE7E7Q35915916-38DFB599-AFAE-4197-9580-46872B14BB57Q36255314-8BA585EE-B1D9-4AA0-8D91-88F4AD218B5EQ36425068-52D0F0C9-1036-4227-AF50-92D767BBD7CAQ36439125-8744E734-27F6-4C42-A2FE-C096258AC37BQ36972700-DD661E04-3C45-4366-8B5F-09BAD3F7158AQ36984240-37ABF6FA-E996-4B11-85D0-9E5246A11095Q37115755-1B84304F-158A-4085-B7EE-7AD91AFA780EQ37122040-EB1BB1B7-E948-4C54-983E-9BA80F134861Q37203775-7E52ABCC-2617-42A3-916B-2252F18FDE88Q37211777-965DF2D8-51D6-4454-921F-57A2EE1048AFQ37251569-2873E2AA-85C4-4BFD-9DE3-60F71DD0CA69Q37288800-BEAC4ACC-2257-401A-B668-5AA7E8E42AA0Q37421034-8658D251-E2B9-46E2-A043-28F16C86A79CQ37633495-E219E171-F481-4944-B222-5004FE20CDA0Q37634512-4995BB45-6161-48CD-BA77-BE2AFF6EFC45Q37823558-80A822C9-A4DA-4DAD-9E89-A166CD6C654FQ38143466-1FECC51A-8A85-4F79-8253-F04020C59560Q38568978-08E65900-04BB-4C64-B7A3-59CB6BB43235Q38614025-DE7B7CA0-5074-4D8B-B694-C60BD79F3FCFQ39127382-9EDC3DA0-544D-41BE-9D0F-4CA7D74DC3B5Q39244930-B4150D50-6573-483A-BA46-8215FF87CF07Q39428374-B4701012-60E6-4893-B318-E64F2918A618
P2860
Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@ast
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@en
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@nl
type
label
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@ast
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@en
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@nl
prefLabel
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@ast
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@en
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@nl
P1476
Clinical manifestations and ma ...... elated mitochondrial toxicity.
@en
P2093
P304
911-36; discussion 898
P356
10.1016/S0149-2918(00)80064-8
P577
2000-08-01T00:00:00Z